WO2011147926A3 - Magnetically responsive membrane structures - Google Patents
Magnetically responsive membrane structures Download PDFInfo
- Publication number
- WO2011147926A3 WO2011147926A3 PCT/EP2011/058654 EP2011058654W WO2011147926A3 WO 2011147926 A3 WO2011147926 A3 WO 2011147926A3 EP 2011058654 W EP2011058654 W EP 2011058654W WO 2011147926 A3 WO2011147926 A3 WO 2011147926A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnetically responsive
- vesicular
- attachment
- membrane structures
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
The present invention is directed towards magnetically responsive vesicular compositions comprising (a) a vesicular structure having a membrane enclosing a cavity and (b) at least one stabilized magnetic nanoparticle embedded in said membrane, and in particular towards lipid and/or polymeric vesicular compositions comprising stabilized superparamagnetic iron oxide nanoparticles. The vesicular compositions may further be functionalized with reactive groups for attachment of active agents or tethers for attachment to surfaces. Methods of preparation and their use in (targeted) delivery of an active agent, as a nanoreactor, for imaging purposes and combinations thereof are also disclosed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11723036.7A EP2575896A2 (en) | 2010-05-26 | 2011-05-26 | Magnetically responsive membrane structures |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10163865 | 2010-05-26 | ||
EP10163865.8 | 2010-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011147926A2 WO2011147926A2 (en) | 2011-12-01 |
WO2011147926A3 true WO2011147926A3 (en) | 2012-05-31 |
Family
ID=44626661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/058654 WO2011147926A2 (en) | 2010-05-26 | 2011-05-26 | Magnetically responsive membrane structures |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2575896A2 (en) |
WO (1) | WO2011147926A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2666456A1 (en) | 2012-05-21 | 2013-11-27 | Natura Bisse International, S.A. | Cometic compositions comprising magnetosomes and uses thereof |
PT3092012T (en) * | 2014-01-07 | 2019-09-18 | Colorobbia Italiana Spa | Magnetic nanoparticles functionalized with cathecol, production and use thereof |
EP3139964B1 (en) * | 2014-05-06 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Magnetoenzymatic carrier system for imaging and targeted delivery and release of active agents |
EP3162361A1 (en) | 2015-11-02 | 2017-05-03 | Universität für Bodenkultur Wien | Improved magnetically reactive vesicular bodies |
FR3045408B1 (en) * | 2015-12-18 | 2021-01-08 | Centre Nat Rech Scient | ASSEMBLIES OF HYDROPHOBIC NANOPARTICLES IN AQUEOUS MEDIUM |
WO2017197310A1 (en) * | 2016-05-13 | 2017-11-16 | University Of Maryland | Synthesis and functionalization of highly monodispersed iron and iron core/iron oxide shell magnetic particles with broadly tunable diameter |
CN110947363A (en) * | 2019-12-04 | 2020-04-03 | 四川农业大学 | Magnetic-drive light carbon sponge for oil-water separation and preparation method thereof |
AU2021342431A1 (en) * | 2020-09-16 | 2023-07-13 | Imagion Biosystems, Inc. | Methods and apparatuses for the synthesis of drug-loaded magnetic micelle aggregates |
CN115121007A (en) * | 2021-03-24 | 2022-09-30 | 南开大学 | Dynamic intelligent membrane based on pH-magnetism dual response and used for efficiently and accurately separating complex oil-water system |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011023A1 (en) * | 1994-10-10 | 1996-04-18 | Nycomed Salutar Inc. | Liposomal agents |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US6251365B1 (en) * | 1997-03-07 | 2001-06-26 | Max-Delbruck-Centrum Fur Molekulare Medizin And Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Specific magnetosome, method for the production and use thereof |
WO2007021236A1 (en) * | 2005-08-19 | 2007-02-22 | Genovis Ab | A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle |
US20070154397A1 (en) * | 2005-12-30 | 2007-07-05 | Industrial Technology Research Institute | Thermosensitive nanostructure for hyperthermia treatment |
US20090004258A1 (en) * | 2007-06-27 | 2009-01-01 | National Health Research Institutes | Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field |
WO2009042895A2 (en) * | 2007-09-26 | 2009-04-02 | Dana-Farber Cancer Institute, Inc. | Reagents for inducing an immune response |
US20110059020A1 (en) * | 2009-09-08 | 2011-03-10 | Fujifilm Corporation | Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same |
WO2011061259A1 (en) * | 2009-11-18 | 2011-05-26 | Nanobacterie | Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
WO2012030134A2 (en) * | 2010-08-30 | 2012-03-08 | Hanwha Chemical Corporation | Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3619746A1 (en) | 1986-06-12 | 1987-12-17 | Basf Ag | SUPER PARAMAGNETIC SOLID PARTICLES |
US5729511A (en) | 1991-02-15 | 1998-03-17 | Discovision Associates | Optical disc system having servo motor and servo error detection assembly operated relative to monitored quad sum signal |
IT1254135B (en) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | ACIL CARNITINE ESTERS WITH LONG CHAIN ALIPHATIC ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, WITH ANTIBACTERIAL ACTIVITY. |
-
2011
- 2011-05-26 EP EP11723036.7A patent/EP2575896A2/en not_active Withdrawn
- 2011-05-26 WO PCT/EP2011/058654 patent/WO2011147926A2/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
WO1996011023A1 (en) * | 1994-10-10 | 1996-04-18 | Nycomed Salutar Inc. | Liposomal agents |
US6251365B1 (en) * | 1997-03-07 | 2001-06-26 | Max-Delbruck-Centrum Fur Molekulare Medizin And Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Specific magnetosome, method for the production and use thereof |
WO2007021236A1 (en) * | 2005-08-19 | 2007-02-22 | Genovis Ab | A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle |
US20070154397A1 (en) * | 2005-12-30 | 2007-07-05 | Industrial Technology Research Institute | Thermosensitive nanostructure for hyperthermia treatment |
US20090004258A1 (en) * | 2007-06-27 | 2009-01-01 | National Health Research Institutes | Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field |
WO2009042895A2 (en) * | 2007-09-26 | 2009-04-02 | Dana-Farber Cancer Institute, Inc. | Reagents for inducing an immune response |
US20110059020A1 (en) * | 2009-09-08 | 2011-03-10 | Fujifilm Corporation | Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same |
WO2011061259A1 (en) * | 2009-11-18 | 2011-05-26 | Nanobacterie | Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
WO2012030134A2 (en) * | 2010-08-30 | 2012-03-08 | Hanwha Chemical Corporation | Iron oxide nanocapsules, method of manufacturing the same, and mri contrast agent using the same |
Non-Patent Citations (2)
Title |
---|
ESTHER AMSTAD ET AL: "Triggered Release from Liposomes through Magnetic Actuation of Iron Oxide Nanoparticle Containing Membranes", NANO LETTERS, vol. 11, no. 4, 13 April 2011 (2011-04-13), pages 1664 - 1670, XP055023851, ISSN: 1530-6984, DOI: 10.1021/nl2001499 * |
ESTHER AMSTAD ET AL: "Ultrastable Iron Oxide Nanoparticle Colloidal Suspensions Using Dispersants with Catechol-Derived Anchor Groups", NANO LETTERS, vol. 9, no. 12, 9 December 2009 (2009-12-09), pages 4042 - 4048, XP055023825, ISSN: 1530-6984, DOI: 10.1021/nl902212q * |
Also Published As
Publication number | Publication date |
---|---|
EP2575896A2 (en) | 2013-04-10 |
WO2011147926A2 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011147926A3 (en) | Magnetically responsive membrane structures | |
WO2011017690A3 (en) | Intracellular delivery of contrast agents with functionalized nanoparticles | |
NZ622843A (en) | Improved lipid formulation | |
WO2011119995A3 (en) | Formulations and methods of use | |
WO2006108405A3 (en) | Nanoparticle/active ingredient conjugate | |
BRPI1014854A2 (en) | "polymer-agent conjugates, particles, compositions, and related methods of use" | |
IL221886A (en) | Composition comprising nanoparticles comprising a taxane and an albumin, combinations of the composition with other agents and uses thereof | |
TR201906255T4 (en) | Stable formulations for lyophilizing therapeutic particles. | |
EP2285350A4 (en) | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles | |
WO2010091183A3 (en) | Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles | |
EP2348834A4 (en) | Methods to produce polymer nanoparticles and formulations of active ingredients | |
EP2673006A4 (en) | Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same | |
WO2012104275A3 (en) | Nanoparticles delivery systems, preparation and uses thereof | |
WO2011017456A3 (en) | Localized delivery of nanoparticles for therapeutic and diagnostic applications | |
WO2010076237A3 (en) | Nanoparticle contrast agents for diagnostic imaging | |
WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
EP2600903A4 (en) | Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same | |
WO2009016433A3 (en) | Oncolytic rhabdovirus | |
WO2011150212A3 (en) | Magnetic nanoparticles | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
WO2007141050A3 (en) | Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications | |
WO2011081430A3 (en) | Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy | |
WO2011070440A3 (en) | Oncolytic rhabdovirus | |
WO2010129819A3 (en) | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | |
EP2432460A4 (en) | Water dispersible glyceryl monooleate magnetic nanoparticle formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11723036 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011723036 Country of ref document: EP |